Navigation Links
12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
Date:10/13/2008

'New Class' of Stent with Polyzene(R)-F Surface Treatment Maximizes Endothelialization; Reduces Restenosis, Thrombogenicity, Need for Long-Term Dual Antiplatelet Therapy

WASHINGTON, Oct. 13 /PRNewswire/ -- Clinical investigators at today's "Innovative Devices and Futuristic Therapies" session during the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, presented 12-month follow-up data from the ATLANTA Trial. The results include zero percent thrombosis in patients discontinuing dual anti-platelet therapy after only 30 days.

The ATLANTA Trial is a first-in-man (FIM), prospective, single center, non-randomized, single-arm study involving 55 patients (76 lesions) treated with the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F surface modification for symptomatic ischemic heart disease due to de novo, obstructive lesions of native coronary arteries. The trial was sponsored by CeloNova BioSciences, Inc., maker of the CATANIA(TM) stent.

At 12 months, in an unusually complex FIM patient population, the results showed zero (0.0) percent stent thrombosis (Academic Research Consortium, or ARC-defined), death, myocardial infarction, stroke, or coronary artery bypass graft. Target lesion revascularization was 10.9 percent (only 3.6 percent clinically driven, 7.3 percent non-clinically driven), with a binary restenosis rate of 6.8 percent (five of 74 lesions analyzed at twelve months). Of note, all patients stopped dual anti-platelet therapy after 30 days, but continued aspirin (100 mg/d) throughout the 12-month period.

The acute angiographic and procedural success rate in the ATLANTA Trial was 100 percent. Independent core laboratories analyzed quantitative coronary angiography and intravascular ultrasound (IVUS) data for all patients immediately after stent implantation and at 6-month follow-up. Further analysis of 1,904 cross sections (19,028
'/>"/>

SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
2. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
3. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
4. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
5. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
6. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
7. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
8. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
9. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 Levi ... been commenced in the United States District Court for ... behalf of investors who purchased Galectin Therapeutics Inc. ("Galectin" ... 2014 and July 28, 2014. For more ... complaint alleges that during the Class Period the Company ...
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, ... leader in noninvasive medical monitoring, today announced that the ... Model 3231 OEM/eHealth finger pulse oximeter for use in ... pulse oximeter plugs into a telemedicine hub or kiosk ... pulse rate in pediatric to adult patients. The Model ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... and Company (NYSE: LLY ) today issued ... and chief executive officer about his meeting today with ... job creation, American innovation and competiveness: "It,s ... and take part in this very important dialogue today ...
... Dec. 15, 2010 Johnson & Johnson (NYSE: ... Worldwide Chairman, Medical Devices & Diagnostics (MD&D) and Sheri ... Chairmen of the Executive Committee and join William C. ... in an expanded Office of the Chairman.  Both appointments ...
Cached Medicine Technology:Lilly Statement Regarding President Obama's Meeting With U.S. Business Leaders 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 3
(Date:8/29/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on sterile convenience surgical packs . , ... convenience surgical packs, by Customed Inc., are recalled ... for the recall is a potential defect found due to ... and infection. The affected products’ manufacture dates were from January ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The Florida ... the Hyatt Regency Orlando last week August 21-24 and ... returned as a presenter. , Dr. Greenstein ... the 21st Century was a standing room session; (2) ... – Doctors of Chiropractic Leading the Way in Injury ...
(Date:8/29/2014)... Canadian Healthy Vending , the largest healthy ... survey of its 200 operators from every region of ... appeal to Canadian consumer seeking refreshment at healthy vending ... five selling healthy snacks and top five selling healthy ... for consumers, employers, and families. Everyone wants to eat ...
(Date:8/29/2014)... 29, 2014 The Department of ... Administration (FDA), Center for Food Safety and Applied ... indefinite quantity (IDIQ) contract and the first two ... “Development, Modernization and Enhancement (DME) for FARM VI” ... , Overarching contract objectives include:, , ...
(Date:8/29/2014)... Under Section 946.300, Qualifications for the Certifying Physician, ... not…advertise in a cultivation center or a dispensing organization.” ... of Illinois has done is create a level of ... their care. The goal is to create a level ... typical prescription medications. Medical steering is a serious issue ...
Breaking Medicine News(10 mins):Health News:Sterile Convenience Surgical Packs by Customed, Inc. Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Sport and Spine Rehab’s CEO Presents at the Florida Chiropractic Association National Convention and Expo 2014 2Health News:Survey Results: What Products Do Canadians Want in Their Healthy Vending Machines? 2Health News:Survey Results: What Products Do Canadians Want in Their Healthy Vending Machines? 3Health News:Team VersaTech and CRGT Win HHS FDA Contract to Support Food Applications Regulatory Management (FARM) System Upgrade 2Health News:Team VersaTech and CRGT Win HHS FDA Contract to Support Food Applications Regulatory Management (FARM) System Upgrade 3Health News:Medical Marijuana Company Provides Solution for Illinois Marketing Regulations 2
... NANJING, China, Aug. 5 /PRNewswire-Asia/ -- Simcere Pharmaceutical ... supplier of branded generic and,innovative anti-cancer pharmaceuticals in China, ... quarter results on Monday, August 17, 2009,after the market ... Ren, and chief financial officer, Frank Zhigang Zhao, will,host ...
... , FORT LAUDERDALE, Fla., Aug. 5 ... leading provider of convenient at-home diet, fitness and healthy lifestyle solutions, today ... results after the U.S. equity markets close on Wednesday, August 12, 2009. ... conference call for investors the following day, Thursday, August 13, beginning at ...
... , PARSIPPANY, N.J., Aug. 5 DSM ... facility has received the( )Potent Compound Safety Certification from ... The Certification is for competency and proficiency in the ... potent drug products, and applies to the site,s potent ...
... , HACKENSACK, N.J., Aug 5 ReGen Biologics, a ... regarding its Menaflex collagen meniscus implant that were made in a ... party unaffiliated with the company. ReGen was unaware of ... on the Internet. The statements made in the release do ...
... , , , ... Michigan-based company dedicated to providing custom filling solutions, is now manufacturing ... for this product category in the market. The product line includes ... a growing trend in the hand-sanitizer market for more gentle formulas ...
... , SAN FRANCISCO, Aug. 5 ... to a study just published in the Journal of Gerontology ... risk for poor health outcomes and complications from other disorders. ... ongoing study of healthy adults aged 65 and older funded ...
Cached Medicine News:Health News:Simcere Pharmaceutical Group to Announce 2009 Second Quarter Earnings on Monday, August 17, 2009 2Health News:eDiets.com(R) to Report Second Quarter Fiscal 2009 Results on Wednesday, August 12, 2009 2Health News:DSM Announces SafeBridge(R) Potent Compound Safety Certification 2Health News:DSM Announces SafeBridge(R) Potent Compound Safety Certification 3Health News:ReGen Biologics Clarifies Recent Press about the Menaflex Device 2Health News:Brain Fitness Reduces Risk of Onset of Depressive Symptoms 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: